Kyverna Therapeutics, Inc. — All Filings
151 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
424B4
424B5
8-A12B
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
FWP
S-1
S-1/A
S-3
S-8
SC 13D
SC 13G
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | 8-K | 0001193125-26-126216 | Mar 26, 2026 | — |
| 10-K | 10-K | 0001193125-26-126242 | Mar 26, 2026 | Dec 31, 2025 |
| S-8 | S-8 | 0001193125-26-126343 | Mar 26, 2026 | — |
| S-3 | S-3 | 0001193125-26-126321 | Mar 26, 2026 | — |
| 4 | 4 | 0001193125-26-110920 | Mar 17, 2026 | Mar 13, 2026 |
| 4 | 4 | 0001193125-26-110941 | Mar 17, 2026 | Mar 13, 2026 |
| 4 | 4 | 0001193125-26-110934 | Mar 17, 2026 | Mar 13, 2026 |
| 4 | 4 | 0001193125-26-091626 | Mar 4, 2026 | Feb 24, 2026 |
| 3 | 3 | 0001193125-26-091628 | Mar 4, 2026 | Feb 24, 2026 |
| 4 | 4 | 0001193125-26-076897 | Feb 26, 2026 | Feb 24, 2026 |
| 3 | 3 | 0001193125-26-076896 | Feb 26, 2026 | Feb 24, 2026 |
| 8-K | 8-K | 0001193125-26-065320 | Feb 24, 2026 | — |
| SCHEDULE 13G/A | — | 0001193125-26-054806 | Feb 17, 2026 | — |
| SCHEDULE 13G/A | — | 0001972690-26-000003 | Feb 17, 2026 | — |
| 3 | 3 | 0001193125-26-046678 | Feb 11, 2026 | Feb 9, 2026 |
| 4 | 4 | 0001193125-26-046665 | Feb 11, 2026 | Feb 9, 2026 |
| SCHEDULE 13G/A | — | 0001104659-26-011469 | Feb 6, 2026 | — |
| 8-K | 8-K | 0001193125-26-034464 | Feb 3, 2026 | Jan 29, 2026 |
| 4 | 4 | 0001193125-26-013021 | Jan 14, 2026 | Jan 12, 2026 |
| 8-K | 8-K | 0001193125-26-009810 | Jan 12, 2026 | Jan 8, 2026 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-25-123596 | Dec 22, 2025 | Dec 18, 2025 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-25-123597 | Dec 22, 2025 | Dec 18, 2025 |
| 424B5 | PROSPECTUS SUPPLEMENT | 0001213900-25-123032 | Dec 18, 2025 | — |
| 8-K | CURRENT REPORT | 0001213900-25-123033 | Dec 18, 2025 | Dec 17, 2025 |
| 4 | 4 | 0001193125-25-323332 | Dec 17, 2025 | Dec 15, 2025 |
| FWP | FREE WRITING PROSPECTUS | 0001213900-25-122555 | Dec 17, 2025 | — |
| 8-K | 8-K | 0001193125-25-318469 | Dec 15, 2025 | — |
| 144 | — | 0001950047-25-010307 | Dec 15, 2025 | — |
| 424B5 | PROSPECTUS SUPPLEMENT | 0001213900-25-121773 | Dec 15, 2025 | — |
| 8-K | 8-K | 0001193125-25-318377 | Dec 15, 2025 | — |
| SCHEDULE 13G | — | 0000919574-25-007080 | Nov 17, 2025 | — |
| 10-Q | 10-Q | 0001193125-25-277584 | Nov 12, 2025 | Sep 30, 2025 |
| 8-K | 8-K | 0001193125-25-277569 | Nov 12, 2025 | — |
| 8-K | 8-K | 0001193125-25-261719 | Nov 3, 2025 | Nov 2, 2025 |
| 8-K | 8-K | 0001193125-25-254571 | Oct 29, 2025 | — |
| 8-K | 8-K | 0001193125-25-254698 | Oct 29, 2025 | — |
| 8-K | 8-K | 0001193125-25-217434 | Sep 25, 2025 | Sep 19, 2025 |
| 8-K | 8-K | 0000950170-25-107300 | Aug 12, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-107321 | Aug 12, 2025 | Jun 30, 2025 |
| 4 | 4 | 0000950170-25-092421 | Jul 1, 2025 | Jun 30, 2025 |
| 3 | 3 | 0000950170-25-092419 | Jul 1, 2025 | Jun 30, 2025 |
| 8-K | CURRENT REPORT | 0001213900-25-059289 | Jun 30, 2025 | — |
| 8-K | 8-K | 0000950170-25-080896 | Jun 3, 2025 | May 29, 2025 |
| 4 | 4 | 0000950170-25-080447 | Jun 2, 2025 | May 29, 2025 |
| 4 | 4 | 0000950170-25-080450 | Jun 2, 2025 | May 29, 2025 |
| 4 | 4 | 0000950170-25-080459 | Jun 2, 2025 | May 29, 2025 |
| 4 | 4 | 0000950170-25-080451 | Jun 2, 2025 | May 29, 2025 |
| 4 | 4 | 0000950170-25-080456 | Jun 2, 2025 | May 29, 2025 |
| 4 | 4 | 0000950170-25-080457 | Jun 2, 2025 | May 29, 2025 |
| 10-Q | 10-Q | 0000950170-25-070325 | May 13, 2025 | Mar 31, 2025 |